Literature DB >> 29797234

Artesunate promotes G2/M cell cycle arrest in MCF7 breast cancer cells through ATM activation.

Lijuan Wen1,2, Lei Liu3, Lina Wen4, Tao Yu2, Fengxiang Wei5,6.   

Abstract

BACKGROUND: Recent studies have revealed that artesunate (ART) has clear anti-tumor activity, suggesting that it could be a good candidate chemotherapeutic agent. In this study, we researched the inhibitory effect of ART on MCF7 cells and explored the possible mechanisms.
METHODS: MTT assay was used to detect the effect of ART on the proliferation of MCF7 cells. Crystal violet staining was used to observe morphological and quantitative changes. Flow cytometry was used to detect the cell cycle of the drug-acting MCF7 cells. In addition, western blotting was used to detect the drug influence on expression of the ATM, phospho-ATM(S1981), H2AX, γH2AX(S139), CHK2 and phospho-CHK2(T68), cdc25C, and phospho-cdc25C(S216).
RESULTS: In the experimental groups, the proliferation of MCF7 cells was inhibited in a dose-dependent manner and the original cell morphology was lost. The number of G2/M phase cells in the experimental groups increased significantly, and the expression of DNA damage response-associated proteins was significantly increased, such as phospho-ATM(S1981), γH2AX(S139), phospho-CHK2(T68), and phospho-cdc25C(S216).
CONCLUSIONS: ART can inhibit cell proliferation and promote G2/M arrest in MCF7 cells through ATM activation and the ensuing "ATM-Chk2-Cdc25C" pathway, thus implicating ART as a novel candidate for breast cancer chemotherapy.

Entities:  

Keywords:  Artesunate; Cell cycle; DNA damage response; MCF7 cell

Mesh:

Substances:

Year:  2018        PMID: 29797234     DOI: 10.1007/s12282-018-0873-5

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  6 in total

Review 1.  Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?

Authors:  Zhaowu Ma; Clariis Yi-Ning Woon; Chen-Guang Liu; Jun-Ting Cheng; Mingliang You; Gautam Sethi; Andrea Li-Ann Wong; Paul Chi-Lui Ho; Daping Zhang; Peishi Ong; Lingzhi Wang; Boon-Cher Goh
Journal:  Front Pharmacol       Date:  2021-12-31       Impact factor: 5.810

Review 2.  Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand.

Authors:  Karim Farmanpour-Kalalagh; Arman Beyraghdar Kashkooli; Alireza Babaei; Ali Rezaei; Alexander R van der Krol
Journal:  Front Plant Sci       Date:  2022-02-07       Impact factor: 5.753

3.  Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway.

Authors:  Sascha D Markowitsch; Olesya Vakhrusheva; Patricia Schupp; Yasminn Akele; Jovana Kitanovic; Kimberly S Slade; Thomas Efferth; Anita Thomas; Igor Tsaur; René Mager; Axel Haferkamp; Eva Juengel
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

4.  Development of artesunate intelligent prodrug liposomes based on mitochondrial targeting strategy.

Authors:  Liwei Gu; Jiaxing Zhang; Dandan Liu; Jiayun Chen; Shuzhi Liu; Qing Peng; Ya Tian; Maobo Du; Junzhe Zhang; Wei Xiao; Shuo Shen; Jigang Wang
Journal:  J Nanobiotechnology       Date:  2022-08-13       Impact factor: 9.429

Review 5.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162

6.  The Metabolic Changes of Artesunate and Ursolic Acid on Syrian Golden Hamsters Fed with the High-Fat Diet.

Authors:  Shichen Pu; Yumin Liu; Shan Liang; Pin Liu; Hongmei Qian; Qian Wu; Yuliang Wang
Journal:  Molecules       Date:  2020-03-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.